A multicentre, randomized, controlled trial evaluating the effectiveness of Probiotic and Peanut Oral Immunotherapy (PPOIT) in inducing desensitisation or tolerance in children with peanut allergy compared with Oral Immunotherapy (OIT) alone and with placebo.
Latest Information Update: 06 May 2024
At a glance
- Drugs PRT 120 (Primary)
- Indications Peanut hypersensitivity
- Focus Therapeutic Use
- Acronyms PPOIT 003
Most Recent Events
- 29 Apr 2024 According to a Prota Therapeutics media release, company has recently secured US$21 million to finance a Phase 3 clinical investigation of its PRT120 oral therapy for peanut allergy.
- 16 May 2022 Results published in the Prota Therapeutics Media Release.
- 18 Feb 2022 New trial record